Cyclic Peptides as Non-carboxyl-terminal Ligands of Syntrophin PDZ Domains by Gee, Stephen H. et al.
Cyclic Peptides as Non-carboxyl-terminal Ligands of
Syntrophin PDZ Domains*
(Received for publication, April 16, 1998, and in revised form, June 5, 1998)
Stephen H. Gee‡§, Stacy A. Sekely¶, Christian Lombardoi, Alexei Kurakin**,
Stanley C. Froehner‡, and Brian K. Kay**‡‡
From the Departments of ‡Physiology and ¶Biology, and the iMacromolecular Interactions Facility, University of North
Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 and **Department of Pharmacology, University of Wisconsin-
Madison, Madison, Wisconsin 537060
Syntrophins, a family of intracellular peripheral
membrane proteins of the dystrophin-associated pro-
tein complex (DAPC), each contain a single PDZ domain.
Syntrophin PDZ domains bind C-terminal peptide se-
quences with the consensus R/K-E-S/T-X-V-COOH, an in-
teraction that mediates association of skeletal muscle
sodium channels with the DAPC. Here, we have isolated
cyclic peptide ligands for syntrophin PDZ domains from
a library of combinatorial peptides displayed at the N
terminus of protein III of bacteriophage M13. Affinity
selection from a library of X10C peptides yielded ligands
with the consensus X-(R/K)-E-T-C-L/M-A-G-X-C-C, where
C represents any hydrophobic amino acid. These pep-
tides contain residues (underlined) similar to the C-ter-
minal consensus sequence for binding to syntrophin
PDZ domains and bind to the same site on syntrophin
PDZ domains as C-terminal peptides, but do not bind to
other closely related PDZ domains. PDZ binding is de-
pendent on the formation of an intramolecular disulfide
bond in the peptides, since treatment with dithiothre-
itol, or substitution of either of the two cysteines with
alanines, eliminated this activity. Furthermore, amino
acid replacements revealed that most residues in the
phage-selected peptides are required for binding. Our
results define a new mode of binding to PDZ domains
and suggest that proteins containing similar conforma-
tionally constrained sequences may be ligands for PDZ
domains.
PDZ1 domains are 80–90-amino acid modules present in
numerous eukaryotic proteins. They were first described as a
series of three internal, repeated elements within the post-
synaptic density (PSD)-95 protein (1). In fact, the name PDZ is
derived from three proteins first recognized to contain repeats
of this domain: PSD-95; the Drosophila discs-large tumor sup-
pressor protein, Dlg; and the mammalian tight-junction protein
zona occludens-1, ZO-1 (2–5). PDZ domains have since been
identified in a large number of multifunctional proteins, many
of which are associated with specialized regions of cell to cell
contact such as tight junctions, septate junctions, and synaptic
junctions (6). The PDZ domain may be an evolutionarily old
domain, as it has been detected in mammalian, nematode,
yeast, plant, and bacterial genomic sequences by computer
analysis (7).
PDZ domains mediate protein-protein interactions by at
least two distinct mechanisms. Certain PDZ domains bind di-
rectly to specific recognition sequences at the C terminus of
transmembrane proteins. For example, the second PDZ domain
of PSD-95 interacts with an S/T-X-V-COOH motif in N-methyl-
D-aspartate receptor 2B subunits (8, 9) and in Shaker-type
potassium channels (10). PDZ domains can also form hetero-
typic dimers with other PDZ domains. For instance, the N-
terminal region of nNOS, which itself contains a PDZ domain,
binds directly to PDZ domains in both PSD-95 and a1-syntro-
phin, a component of the dystrophin-associated protein com-
plex (DAPC) (11). A third possible mode of interaction, in which
the consensus binding sequence is located internally, is sug-
gested by the observation that the PDZ domain in the Drosoph-
ila InaD photoreceptor protein interacts with a S/T-X-V se-
quence near, but not at, the C terminus of the transient
receptor potential Ca12 channel (12). More recently, the PDZ
domain in the actinin-associated LIM protein has been shown
to bind to unidentified sequences within the internal spectrin-
like repeats of a-actinin (13). Thus, PDZ domains may take
part in several diverse types of interactions.
The structures of several PDZ domains, alone and complexed
with peptides, have been deduced (14–16). The PDZ domain
has an overall structure very much like the phosphotyrosine
binding domain, even though they are unrelated in function
(17, 18). Essentially, it is a globular domain formed by six b
strands (designated bA–bF) and two a helices (designated aA
and aB) arranged into an up-and-down b-barrel (14, 15). Anal-
ysis of the crystal structure of the third PDZ domain of Dlg
revealed a groove on the surface that ends in a conserved
hydrophobic pocket created by the bB strand, the aB helix, and
a loop connecting the bA and bB strands (15). The crystal
structure of a S/T-X-V-COOH peptide ligand complexed with
the third PDZ domain of PSD-95 revealed that the peptide
binds within this groove and that the terminal carboxylate
group of the peptide inserts into the hydrophobic pocket (14).
The specificity of binding is determined by the interaction of
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certain residues in the PDZ domain with side chains of the last
three or four residues of the C-terminal peptide.
The specificities of several different PDZ domains have been
defined using combinatorial peptide libraries (16, 19, 20). The
peptide ligand preferences of one family of nine PDZ domains
was shown to be X-S/T-X-V/I-COOH, where X was either any,
or a preferred amino acid, depending on the PDZ domain (19).
Recently, the PDZ domain of a1-syntrophin was shown to be
selective for peptides with a similar motif, R/K/Q-E-S/T-X-V-
COOH (16). The C termini of two skeletal muscle sodium chan-
nels (NaChs) conform to this consensus and bind directly to the
PDZ domains of a1-, b1-, and b2-syntrophins (21). This interac-
tion mediates the association of NaChs with the DAPC and
links them to the cortical actin cytoskeleton and the extracel-
lular matrix.
In this report, we utilized phage-displayed combinatorial
peptide libraries to define the specificities of the PDZ domains
of a1-, b1-, and b2-syntrophin. We have isolated novel peptide
ligands for syntrophin PDZ domains which conform to the
consensus sequence K/R-E-(S/T)-X-(V/L/I/M)-COOH previously
determined to bind syntrophin PDZ domains, but lack a C-
terminal carboxylate group. Instead, these peptides are able to
interact with syntrophin PDZ domains when fused to either the
N terminus of a bacteriophage M13 capsid protein or bacterial
alkaline phosphatase (AP). Cyclization of these peptides
through intramolecular disulfide bond formation was found to
be essential for binding to syntrophin PDZ domains since re-
duction with DTT, or replacement of cysteines with alanine,
eliminated this interaction. These cyclic peptide ligands appear
to be specific for syntrophin PDZ domains since several other
closely related PDZ domains do not bind them. Additional
experiments showed that these peptides bind to the same site
on syntrophin PDZ domains as C-terminal peptides and sug-
gest that they act as C-terminal peptide mimetics. Our results
define a novel mode of binding of peptide ligands to PDZ do-
mains and suggest that proteins containing similar conforma-
tionally constrained peptide sequences may be capable of in-
teracting with other PDZ domain-containing proteins.
EXPERIMENTAL PROCEDURES
Isolation and Characterization of Syntrophin PDZ Domain-binding
Phage—Glutathione S-transferase (GST) fusion proteins of the PDZ
domain of mouse a1-, b1-, and b2-syntrophins were prepared in the
following manner. Oligonucleotides were designed to flank the PDZ
domains and the regions were selectively amplified from cDNA clones
by polymerase chain reaction (22). The amplified segments were sub-
cloned between the BamHI and EcoRI sites of pGEX (Amersham Phar-
macia Biotech) and recombinants were verified by DNA sequencing.
GST fusion proteins were expressed and purified according to the man-
ufacturer’s instructions.
To screen the phage-displayed combinatorial peptide libraries, mi-
crotiter plate wells were first coated with 1 mg of a GST fusion protein
of the b1-syntrophin PDZ domain, blocked with SuperBlockt (Pierce),
and then 1014 recombinant phage particles were added. After incuba-
tion for 2 h at room temperature, the wells were washed of excess
phage, and the bound phage were recovered by the addition of 50 ml of
glycine, pH 2.0. Two libraries were screened in this manner: X12 and
X10C, where X is any amino acid encoded by the degenerate NN(G/T)
codons. These peptides were displayed at the N terminus of mature
capsid protein III of phage particles (23). After three rounds of affinity
selection, isolates were tested for binding to GST-PDZ fusion proteins
by ELISA (Amersham Pharmacia Biotech). The DNA sequences of
binding phage were determined and the peptide sequences predicted
with MacVectort software (IBI-Kodak, New Haven, CT).
The binding properties of isolated phage were determined by ELISA.
Microtiter plate wells were coated with equal amounts of various GST
fusion proteins, washed, blocked with bovine serum albumin and then
incubated with 1011 plaque- forming units. The amount of bound phage
was quantitated with anti-phage antibodies conjugated to horseradish
peroxidase (Amersham Pharmacia Biotech). The ability of the phage to
bind to wells was also monitored in the presence of the reducing agent,
DTT.
Construction and Testing of AP Fusion Proteins—The insert of the
phage isolate F was amplified by the polymerase chain reaction with
flanking oligonucleotides, digested with SalI and XbaI, and ligated into
pMY101 (24). Bacteria, harboring the resulting recombinant plasmid,
secreted a chimeric protein with the peptide fused to the N terminus of
Escherichia coli AP into the culture medium, upon induction with
isopropyl-b-D-thiogalactopyranoside. The conditioned medium was then
added to microtiter plate wells coated with various proteins, with or
without soluble competitor peptides, and the amount of enzyme re-
tained in the wells after 1 h incubation was quantitated with the
colorimetric substrate, p-nitrophenyl phosphate. Optical absorbance of
wells was measured at 405 nm wavelength with a plate reader (Molec-
ular Devices, Sunnyvale, CA).
Alanine Scan of the Syntrophin PDZ Domain Ligand—Each amino
acid of one ligand sequence, AKETCLAGYYC, was independently sub-
stituted by alanine and fused to the N terminus of AP using standard
molecular biological methods. A peptide ligand-AP fusion, in which the
two cysteines were substituted with serines, was generated in the same
manner. All 12 chimeric proteins were tested for their ability to bind
GST fusion proteins of the a1-, b1-, and b2-syntrophin PDZ domains
immobilized on microtiter plates. Wells were coated with 0.5 mg of the
purified syntrophin PDZ domain fusion proteins or with anti-FLAG M1
antibody (Boehringer Mannheim), and blocked with 1% bovine serum
albumin in 0.1 M NaHCO3, pH 8.3, for 1 h at room temperature. Wells
were incubated for 2 h at room temperature with bacterial culture
media conditioned with each of the peptide ligand-AP fusions (24). After
extensive washing with phosphate-buffered saline, pH 7.4, and 0.1%
Tween 20, the amount of the AP retained in the wells was quantitated
after addition of p-nitrophenyl phosphate by measuring optical absorb-
ance at 405-nm wavelength.
Blot Overlay and Affinity Purification Experiments—N-terminal bi-
otinylated peptides corresponding to the phage F insert (AKET-
CLAGYYCS-COOH), the C terminus of the SkM1 skeletal muscle so-
dium channel (PGQTVRPGVKESLV-COOH) and the C terminus of Fas
(ENSNFRNEIQSLV-COOH) were synthesized. All synthetic peptides
contained an N-terminal three amino acid (SGS) linker sequence. The
identities of all peptides were determined by mass spectroscopy. Pep-
tides were dissolved either in water, or in Me2SO, then diluted with
water until the organic solvent was less than 1%. The binding of the
peptides to various proteins was followed in two ways. Overlay assays
with biotinylated peptides (used at a final concentration of 1 mM) were
performed as described previously (21). Isolation of syntrophins from
skeletal muscle extracts with peptides coupled to streptavidin-linked
beads (Sigma) was carried out as described previously (21).
Mass Spectrometry—Measurements of peptide F mass were per-
formed on a Micromass Quattro II triple quadrapole electrospray ioni-
zation mass spectrometer. Peptide F was dissolved in neat methanol
and infused directly into the electrospray source. The m/z range for
data collection was set from 700 to 2000.
Surface Plasmon Resonance Measurements—All experiments were
performed on a BIAcore 2000 instrument (BIAcore Inc., Piscataway,
NJ) at the University of North Carolina Macromolecular Interactions
Facility. Biotinylated peptides were immobilized on Neutravidin
(Pierce)-coated sensor chips as described previously (21). Increasing
concentrations of syntrophin PDZ domains were injected onto the pep-
tide surfaces at a flow rate of 20 ml/min for 2 min in 20 mM HEPES, pH
7.5, 150 mM NaCl, 3 mM EDTA, and 0.005% surfactant P-20. Between
successive measurements the surfaces were regenerated with 10 mM
HCl (2-min contact time). Binding to Neutravidin alone was also meas-
ured and was used to subtract nonspecific interactions. Blank sensor-
grams recorded for injection of running buffer were also subtracted.
Background corrected sensorgrams were fitted to a single site binding
model using the numerical integration functions of the BIAevaluation
3.0 software (BIAcore AB, Uppsala, Sweden). The steady state binding
value, Req, for each PDZ analyte concentration was then plotted as a
function of analyte concentration. To derive binding constants, data
from these plots were analyzed by the steady state affinity binding
model provided in the BIAevaluation software (25–27). The reported
values are the average of four separate experiments.
RESULTS
Isolation of Syntrophin PDZ Domain-binding Phage—Three
syntrophin isoforms, a1, b1, and b2, are encoded by separate
genes but have an identical domain organization (28, 29). Each
syntrophin contains a single PDZ domain, which is 78–84%
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identical in primary structure among the three isoforms (28).
To identify peptide ligands for syntrophin PDZ domains, we
screened a bacteriophage M13 library displaying combinatorial
peptides of the type X12 (where X is any amino acid encoded by
NN(G/T) codons) with a recombinant GST fusion protein of the
b1-syntrophin PDZ domain. After three rounds of affinity se-
lection, individual phage isolates were tested for binding. No
positive isolates were selected using this library. We next
screened a library of the type X10C, where every peptide had 10
random residues followed by a fixed cysteine residue. Seven
independent phage were isolated from a library of 109 different
peptides that encoded three different, but related peptide se-
quences (Fig. 1). The peptides share the consensus sequence
X-(R/K)-E-T-C-(L/M)-A-G-X-C-C-COOH, where C represents a
hydrophobic residue.
Specificity of Phage Peptide Isolates—Next, we determined
the specificity of three phage isolates, each representing a
unique peptide sequence, for different PDZ domains. Microtiter
wells coated with equivalent amounts of GST fusion proteins of
a1-, b1-, and b2-syntrophin PDZ domains, as well as a fusion
protein containing the PDZ domain of nNOS (amino acids
1–150), were incubated with equivalent amounts (1010 plaque-
forming units) of phage particles. The binding of the phage
particles was monitored by ELISA. Positive and negative con-
trol targets consisted of GST fused to the Src homology 3 (SH3)
domain and GST alone, respectively. Phage isolates B, D, and
F bound best to the b2-syntrophin PDZ domain and nearly
equivalently to the PDZ domains of a1- and b1-syntrophin (Fig.
2A). In contrast, the three phage isolates did not bind to either
the nNOS PDZ or Src SH3 domains above background (i.e. GST
alone). Moreover, phage displaying a peptide ligand for the Src
SH3 domain bound to the GST-Src SH3 domain but not to any
of the PDZ domains tested. Thus, although the peptides were
selected with the b1-syntrophin PDZ domain, they bound better
to the b2-syntrophin PDZ domain than to either a1 or b1. These
differences in binding may reflect either the different specific-
ities of the PDZ domains or the ability to retain their native
conformations when immobilized on plastic.
To demonstrate that the peptide sequences shown in Fig. 1
are necessary and sufficient for binding, one insert sequence
(phage F, AKETCLAGYYC) was cloned into the pMY101 vector
(24). Bacteria harboring the resulting recombinant produce an
enzymatically active E. coli AP fusion protein with the peptide
at the N terminus and secrete it into the culture supernatant.
Equivalent amounts of this fusion protein (designated peptide
F-AP) or a Src SH3 ligand-AP fusion protein were incubated in
microtiter wells containing a variety of GST fusion proteins. As
shown in Fig. 2B, peptide F-AP bound best to the PDZ domain
of b2-syntrophin and somewhat less well to the PDZ domains of
a1- and b1- syntrophin, mirroring the specificity observed in the
phage ELISA experiment. Moreover, peptide F-AP did not bind
to the PDZ domain of nNOS, the Src SH3 domain, or GST
alone. In contrast, the Src SH3 ligand-AP fusion bound only to
the GST-Src SH3 fusion protein. These results demonstrate
that the phage F peptide sequence is sufficient for binding to all
three syntrophin PDZ domains, even when fused to the N
terminus of AP.
Isolated Peptides Require Conformational Constraint for
Binding—Even though the location of only one cysteine was
specified within the X10C peptides, all three isolates had a
second cysteine spaced six residues from the first. To determine
whether or not these cysteine residues were disulfide-bridged
in the phage-displayed peptides, we tested the effect of the
reducing agent DTT on binding. Equivalent numbers of phage
particles were incubated in microtiter wells coated with ap-
proximately equal amounts of the b1-syntrophin PDZ domain
fusion protein and the extent of binding was determined by
phage ELISA. As shown in Fig. 3, binding of three phage
isolates (B, E, and F) to the target decreased with increasing
DTT concentration. Fifty percent inhibition (IC50) was ob-
served at approximately 2–5 mM DTT. Since PDZ domains lack
disulfide bonds, this decreased binding can be attributed to the
reduction of disulfide bonds in the displayed peptides by DTT.
FIG. 1. Alignment of amino acid sequences of syntrophin PDZ
domain-binding peptides. Phage were affinity selected from a X10C
peptide library (where X is any amino acid encoded by NN(G/T) codons)
with a GST fusion protein of the b1-syntrophin PDZ domain. Three
different sequences were present among the seven isolates. The number
of times each peptide was represented by a unique phage isolate is
indicated at the right. The peptides share the motif X-(R/K)-E-T-C-(L/
M)-A-G-C-C, where C indicates any hydrophobic amino acid. Invariant
residues in the peptide are shaded, and the one fixed cysteine residue in
the library is boxed.
FIG. 2. Binding specificity of phage isolates. A, phage isolated
with the b1-syntrophin PDZ domain bind to all three syntrophin PDZ
domains. Equivalent numbers of phage particles were added to micro-
titer wells coated with 1 mg each of GST fusion proteins of the PDZ
domains of a1-, b1-, or b2-syntrophin (GST-a1-PDZ, GST-b1-PDZ, or
GST-b2-PDZ), the PDZ domain of nNOS (GST-nNOS PDZ), or the SH3
domain of Src (GST-Src SH3). The amounts of three b1-syntrophin
PDZ-binding phage (B, D, and F) and one Src SH3-binding phage
(SrcT12) bound to these proteins or to GST alone (GST) was determined
by phage ELISA. B, the phage F insert binds to syntrophin PDZ do-
mains when fused to the N terminus of AP. Equivalent amounts of the
phage F insert fused to bacterial AP (Peptide F-AP) or the Src SH3-
ligand fused to AP (Src SH3 l-AP) were added to microtiter wells coated
with 1 mg of various target GST fusion proteins (noted below the x axis).
Binding was monitored by optical absorbance at 405 nm after addition
of p-nitrophenyl phosphate to the wells. For A and B, values are the
average of triplicate determinations from one representative experi-
ment. Error bars indicate standard error of the mean.
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In contrast, the binding of a Src SH3 domain-binding phage
(30) to the Src SH3 domain was unaffected over the same range
of DTT concentrations. In this case neither the SH3 domain nor
the peptide ligand have cysteines. The binding of the peptide
F-AP fusion protein to syntrophin PDZ domains was also DTT
sensitive (not shown) suggesting that it forms disulfide bonds
as well. These data suggest that conformational constraint
imparted by the disulfide bond in these peptides is required for
binding to syntrophin PDZ domains.
To test this idea directly, we substituted both cysteines in the
peptide F sequence with serines. This simultaneous replace-
ment completely abolished binding of the peptide F-AP fusion
to all three syntrophin PDZ domains (Fig. 4), confirming the
importance of the structural constraint of the peptide for bind-
ing. To evaluate the contribution of each residue in the peptide
to the binding of syntrophin PDZ domains, we produced pep-
tides with alanine substitutions at each position. Consistent
with the results of the serine replacement, alanine-substitution
of either cysteine resulted in a complete loss of binding (Fig. 4).
Furthermore, substitution of most residues in the peptide
greatly diminished binding to all three PDZ domains, whereas
alanine-substitution of the lysine at position 2 (numbering
from the N terminus) and the tyrosine at position 10 resulted in
only a partial loss of binding. Interestingly, alanine-substitu-
tion of the tyrosine at position 9 improved the apparent binding
to all three syntrophin PDZ domains. This residue was the
least conserved among the three initial peptide ligands for the
b1- syntrophin PDZ domain, suggesting that there is potential
to improve the binding efficiency of this ligand further by
varying the identity of the residue at this position.
Isolated Cyclic Peptides are Structural Mimics of C-terminal
Peptides with an S/T-X-V Motif—We recently reported that
peptides corresponding to the C terminus of two skeletal mus-
cle sodium channels (designated SkM1 and SkM2) with the
motif R/K-E-S/T-X-V-COOH, bound strongly to syntrophin PDZ
domains (21). Schultz et al. (16) obtained a similar consensus
(R/K/Q-E-S/T-X-V-COOH) for a1-syntrophin PDZ domain li-
gands using combinatorial peptide libraries. Together, our re-
sults define the ligand preferences of syntrophin PDZ domains.
Close inspection of the consensus sequence in Fig. 1 (X-R/K-E-
T-C-L/M-A-G-X-C-C) revealed a remarkable likeness (residues
underlined) to the C-terminal consensus for binding to syntro-
phin PDZ domains. To test the hypothesis that the phage-
displayed peptides isolated here bind syntrophin PDZ domains
at the same site as C-terminal peptides, peptide F-AP and Src
SH3 ligand-AP fusion proteins were added to microtiter wells
coated with the b1-syntrophin PDZ domain fusion protein in
the presence of increasing concentrations of soluble C-terminal
peptides. Binding of peptide F-AP to the b1- syntrophin PDZ
domain was blocked by the SkM1 peptide (K-E-S-L-V-COOH)
but not by a peptide corresponding to the C terminus of the Fas
antigen (I-Q-S-L-V-COOH), a ligand for the PDZ domain of the
Fas-associated protein tyrosine phosphatase PTPL1/Fas-asso-
ciated protein-1 (31). The IC50 value of the SkM1 peptide was
;30 mM. Neither of the two peptides blocked, at any concentra-
tion tested, the binding of the Src SH3 ligand-AP to the Src
SH3 domain fusion protein.
FIG. 3. Effect of the reducing agent DTT on the binding of
phage isolates to the PDZ domain of b1-syntrophin. Equivalent
amounts (1011 plaque-forming units) of phage particles (PDZ binding
phage clones B, E, and F and Src SH3 binding clone T9) were added to
microtiter wells coated with GST fusion proteins of either the b1-
syntrophin PDZ domain or the Src SH3 domain, in the presence of
varying concentrations of DTT. The amount of bound phage particles
was monitored by phage ELISA. The optical density (O.D.) in single
wells was determined at 405 nm. The binding of the PDZ phage, but not
the Src SH3 phage (src T9), was sensitive to DTT. Note that disulfide-
bridged cysteines are not present in either the syntrophin PDZ domain,
or the Src SH3 domain and its binding phage.
FIG. 4. Alanine scan of the phage F peptide sequence. Equiva-
lent amounts (0.5 mg/well) of the a1-, b1-, and b2-syntrophin PDZ do-
main fusion proteins or anti-FLAG M1 antibody were immobilized in
microtiter plate wells and incubated with culture media conditioned by
the indicated variants of the phage F peptide sequence (A-K-E-T-C-L-
A-G-Y-Y-C) fused to a secreted bacterial AP. All the peptide-AP fusions
carried the FLAG epitope at their N termini. Interaction between the
FLAG epitope and anti-FLAG M1 antibodies was used to assure expo-
sure of the wells to equivalent amounts of AP fusion protein. The
amount of the AP enzyme activity retained in the wells was determined
spectrophotometrically by optical absorbance at 405 nm for triplicate
samples. Error bars indicate standard error of the mean. The wild type
peptide F sequence is boxed. Alanine and serine substitutions in the
peptide ligand sequence are shaded.
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The PDZ domain of a1-syntrophin binds directly to nNOS,
presumably by forming PDZ:PDZ heterodimers (11). As previ-
ously reported, the SkM2 NaCh C-terminal peptide inhibited
the binding of nNOS to syntrophin PDZ domains (21). We
tested whether the phage F peptide sequence could similarly
block nNOS binding. For these studies we chemically synthe-
sized a peptide corresponding to the phage F insert (designated
peptide F). To confirm that the two cysteine residues in the
synthetic peptide were disulfide-bonded, the peptide was ana-
lyzed by mass spectrometry. The presence of a peak in the mass
spectral analysis, corresponding in mass to the peptide lacking
two H atoms, confirmed that the peptide was cyclized (data not
shown). As shown in Fig. 5B, addition of 1 mM peptide F sub-
stantially reduced the interaction between nNOS and all three
syntrophin PDZ domains, with 10 mM peptide producing near
complete inhibition. Since peptide F does not bind to the nNOS
PDZ domain (Fig. 2, A and B), antagonism of the nNOS-syn-
trophin PDZ interaction presumably occurs via binding of the
peptide to the same site of the syntrophin PDZ domain as the
nNOS PDZ domain. These data add further support to the
conclusion that peptide F binds to the same site as C-terminal
syntrophin PDZ ligands.
Peptide F Binds Specifically and with High Affinity to Syn-
trophin PDZ Domains—We further defined the specificity of
the peptide F in overlay experiments using several different
PDZ domains, a1-, b1-, and b2-syntrophin PDZ domain fusion
proteins, two overlapping nNOS fusion proteins containing the
PDZ domain, and fusion proteins of PSD-93 and PSD-95 con-
taining two and three PDZ domains, respectively. When fusion
proteins, that had been resolved by SDS-polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes,
were incubated with a peptide corresponding to the C terminus
of the N-methyl-D-aspartate receptor 2B subunit (NR2B), a
strong signal corresponding to the position of the intact PSD-93
and PSD-95 fusion proteins was observed, as expected (8, 9, 32)
(Fig. 6, panels CBB and NR2B). In comparison, binding of the
NR2B peptide to syntrophin PDZ domains was observed only
with longer exposures (not shown), consistent with previous
data showing that NR2B peptide binds weakly to the PDZ
domain of syntrophins. As shown in Fig. 6 (panels SkM2 and
Peptide F), a significant fraction of all three syntrophin PDZ
domain fusion proteins consistently migrated in SDS-poly-
acrylamide gels as ;60-kDa bands, twice the size expected. The
basis for this apparent dimerization is not known. As reported
previously, a peptide corresponding to the SkM2 NaCh C ter-
minus bound to both the monomeric and dimeric forms of all
three syntrophin PDZ domain fusion proteins (Fig. 6, panel
SkM2) (21). SkM2 also bound to fusion proteins of both PSD-93
and PSD-95. In contrast, peptide F bound to all three syntro-
phin PDZ domains, but not to the PDZ domains of nNOS,
PSD-93, or PSD-95 (Fig. 6, panel Peptide F). None of the pep-
tides tested bound to either of the nNOS PDZ domain fusion
proteins or to GST alone. These results further demonstrate
the specificity of peptide F for syntrophin PDZ domains and
that the peptide F sequence can bind syntrophin PDZ domains
when removed from the context of a fusion protein.
The affinity of syntrophin PDZ domains for peptide F was
measured by surface plasmon resonance. In these experiments,
increasing concentrations (31 nM to 4 mM) of syntrophin PDZ
domain fusion proteins were allowed to bind to peptide F (Fig.
7A) and the SkM2 peptide (Fig. 7B) immobilized on a sensor
chip. Analysis of the steady-state binding yielded overall Kd
values of ;300–800 and ;100–300 nM, respectively. These
results are summarized in Table I. In both cases, the b2-PDZ
fusion protein had a somewhat lower affinity than either the
a1-PDZ or b1-PDZ fusion proteins, even though the b2-PDZ
FIG. 5. Peptide F competes with C-terminal peptides and
nNOS for binding to syntrophin PDZ domains. A, competition of
peptide F-AP binding to syntrophin PDZ domains by the C terminus of
the SkM1 NaCh. Equivalent amounts of the peptide F-AP or Src SH3
ligand-AP fusion proteins were added to microtiter plate wells coated
with 1 mg each of GST fusion proteins of the b1-syntrophin PDZ domain
or the Src SH3 domain. Wells were incubated with soluble peptides
corresponding to the C-terminal 13 amino acids of the Fas antigen or
the SkM1 NaCh. The amount of bound AP fusion proteins was deter-
mined colorimetrically by optical absorbance at 405 nm for triplicate
samples. Error bars indicate standard error of the mean. Values were
normalized to the binding levels measured in the absence of added
peptide (not shown). B, competition of nNOS binding to syntrophin PDZ
domains by peptide F. Purified syntrophin PDZ domain fusion proteins
were resolved by SDS-polyacrylamide gel electrophoresis and trans-
ferred to a nitrocellulose membrane. Identical blots were incubated
with a GST-nNOS (1–150) fusion protein either alone (left panel) or in
the presence of 1 mM (middle panel) or 10 mM (right panel) peptide F.
Bound nNOS was detected with a monclonal antibody to nNOS followed
by an horseradish peroxidase-conjugated goat anti-mouse secondary
antibody and chemiluminescence.
FIG. 6. Specificity of peptide F. Approximately 5 mg each of the
indicated PDZ domain fusion proteins were resolved by SDS-polyacryl-
amide gel electrophoresis and were either stained with Coomassie Bril-
liant Blue (CBB), to determine the position and relative amount of each
fusion protein, or transferred to nitrocellulose membranes. Identical
blots were overlaid with biotinylated peptides corresponding to the C
terminus of the NR2B, the SkM2 skeletal muscle NaCh (SkM2), or
peptide F that had been preconjugated to streptavidin-horseradish
peroxidase. Bound peptide-streptavidin-horseradish peroxidase com-
plexes were detected by chemiluminescence. Peptide F binds to both the
monomer and dimer forms of syntrophin PDZ domains, but not to the
PDZ domains of nNOS, PSD-93, or PSD-95. Molecular mass markers
(kilodaltons) are indicated at the left of each blot.
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domain bound more phage than did a1 or b1 in ELISA assays
(Fig. 2, A and B). It is possible that these results reflect differ-
ences in the ability of the fusion proteins to retain their native
conformation when adsorbed to plastic as compared with that
in solution.
We next asked if the affinity of peptide F for syntrophin PDZ
domains was sufficient to bind native syntrophins from tissue
extracts. Approximately equal amounts of the SkM2 peptide or
peptide F were coupled to streptavidin-agarose and used to
isolate syntrophins from Triton X-100 extracts of mouse skel-
etal muscle membranes. Fig. 8 shows that peptide F isolated
approximately half the amount of syntrophin than did the
SkM2 peptide. Although not strictly quantitative, these results
are consistent with the approximately 2-fold higher affinity of
SkM2 than peptide F for recombinant syntrophin PDZ domains
(Table I). Streptavidin-agarose alone did not bind syntrophins
detectably.
Syntrophin PDZ Domains Cannot Accommodate Additional
Residues following the Hydrophobic Residue in Linear Pep-
tides—Collectively, our results suggest that peptide F binds to
the same site on syntrophin PDZ domains as C-terminal pep-
tide ligands. However, previous studies have shown that PDZ
domains cannot accommodate additional residues following the
C-terminal hydrophobic residue. For example, the addition of
an alanine to the C terminus of Fas abolished binding to the
PDZ domains of the protein-tyrosine phosphatase PTPL1/Fas-
associated protein-1 (33). One possibility is that the peptide
binding groove in syntrophin PDZ domains is long or deep
enough to contain additional residues. To test this possibility,
we synthesized a peptide corresponding to the C terminus of
SkM2 with an additional alanine residue at the C terminus. As
shown in Fig. 9, this peptide did not bind to the PDZ domain of
a1-syntrophin. Thus, syntrophin PDZ domains, like other PDZ
domains, cannot accommodate additional residues following
the hydrophobic amino acid at the C terminus.
DISCUSSION
We have used an N-terminal phage-displayed peptide library
to identify cyclic peptides with the motif X-R/K-E-T-C-L/M-A-
G-X-W/Y-C that bind specifically to syntrophin PDZ domains.
These conformationally constrained peptide ligands are similar
to the carboxyl-terminal sequence R/K/Q-E-S/T-X-V-COOH
previously demonstrated to bind syntrophin PDZ domains (16,
21), except that, in these peptides, this sequence lacks a free
carboxylate group which has been shown to contribute signifi-
cantly to the peptide-PDZ domain interaction (14). The binding
of the phage-displayed peptides is dependent on cyclization of
this sequence by a pair of disulfide-bridged cysteines. Our data
suggest that these cyclic peptides mimic C-terminal peptides
and may be useful as specific inhibitors of syntrophin PDZ
domain interactions.
Phage-displayed libraries have been used to isolate high
affinity cyclic ligands for other proteins including integrins
(34), the erythropoietin receptor (35), the Grb2 SH2 domain
(36), and calmodulin (37). In most cases these peptide ligands
do not resemble the primary sequence of the natural interact-
FIG. 9. The addition of an alanine to the C terminus of the
SkM2 NaCh peptide abolishes binding to the a1-syntrophin PDZ
domain. The binding of purified a1-syntrophin PDZ domain fusion
protein to the SkM2 NaCh C-terminal peptide and to the same sequence
with a C-terminal alanine extension (SkM2-Ala) was measured by
surface plasmon resonance. Robust binding of the a1-PDZ domain to the
SkM2 peptide (upper trace) was observed. In contrast, there was no
detectable binding of the a1-PDZ domain to SkM2-Ala (lower trace).
TABLE I
Dissociation constants for syntrophin PDZ-binding peptides
The binding of various concentrations of the indicated syntrophin
PDZ domain fusion proteins to the SkM2 NaCh C-terminal peptide and
to peptide F was measured by surface plasmon resonance. The steady-
state binding values for each PDZ analyte concentration were plotted as
a function of analyte concentration and binding constants were derived
using a steady state affinity binding model.
Peptide
Syntrophin PDZ domain fusion protein
a1-PDZ b1-PDZ b2-PDZ
nM
F 359 6 40a 382 6 88 786 6 100
SkM2 112 6 10 217 6 23 321 6 18
a Values are shown 6 S.D. and are the average of four separate
determinations from two different experiments. Each determination
comprises 10 different fusion protein concentrations.
FIG. 7. Surface plasmon resonance analysis of the peptide F-
syntrophin PDZ domain interaction. The binding of recombinant
syntrophin PDZ domains to biotinylated peptides immobilized on the
surface of a sensor chip was detected by changes in resonance units
(RU) over time. A, superimposed sensorgrams of the binding of the
a1-syntrophin PDZ domain fusion protein to peptide F at different
concentrations (31 nM to 4 mM). B, binding of the a1-syntrophin PDZ
fusion protein to the SkM2 NaCh C-terminal peptide over the same
range of concentrations. Binding constants derived from these sensor-
grams are summarized in Table I.
FIG. 8. Affinity isolation of syntrophins from muscle extracts
with peptide F. Mouse skeletal muscle extracts were incubated with
approximately equal amounts of the SkM2 NaCh C-terminal peptide
(SkM2) or peptide F (Pept. F) bound to streptavidin-agarose beads, or
with beads alone (2). Bound proteins were resolved by SDS-polyacryl-
amide gel electrophoresis and immunoblotted for syntrophins with a
pan-specific monoclonal antibody.
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ing proteins. Instead, they act as structural mimics. The intra-
chain disulfide bonds of these peptides constrain them into a
conformation that is favorable for strong binding. Accordingly,
we found that substitution of both cysteines with serines, or of
either cysteine with alanine, completely eliminated the syntro-
phin PDZ-binding activity of one cyclic peptide. Consistent
with the idea that the cyclic conformation of these peptides is
important, we also found that syntrophin PDZ domains did not
bind any peptides from a library (X12) encoding linear peptides.
This negative result is in agreement with Songyang et al. (19),
who found that none of the nine PDZ domains they investigated
retained specific peptides from a library encoding non-C-termi-
nal linear peptide sequences.
Although the affinity of peptide F for syntrophin PDZ do-
mains was 2–3-fold lower than the SkM2 peptide, the interac-
tion was of sufficient strength to isolate native syntrophins
from detergent extracts (Fig. 8). Alanine-substitution of the
tyrosine at position 9 of the peptide produced a peptide that
bound stronger to all three recombinant syntrophin PDZ do-
mains than the parental sequence. These data suggest that it
may be possible to isolate higher affinity peptide ligands for
syntrophin PDZ domains by varying the identity of the amino
acid at this position. Moreover, these peptides should serve as
an excellent starting point for the design of compounds which
mimic C-terminal ligands of syntrophin PDZ domains.
Our results are entirely consistent with the idea that the
cyclic peptides isolated here bind to syntrophin PDZ domains in
the same manner as homologous C-terminal peptides, even
though they lack a free carboxylate group. This binding is
contingent upon a constrained conformation provided by an
intramolecular disulfide bond which may allow residues follow-
ing the hydrophobic residue (L/M; which is normally at the C
terminus) to bend away from the peptide binding groove. This
is likely to be an essential feature of these cyclic peptides since
additional residues following the hydrophobic residue in linear
peptides cannot be accommodated (Fig. 9). Syntrophin PDZ
domains also bind to regions of nNOS that contain a PDZ
domain (21). Since the PDZ domain of nNOS is not at the C
terminus, this interaction cannot occur via a C-terminal pep-
tide sequence. One possibility is that a constrained sequence in
nNOS mediates the binding of the nNOS PDZ domain to syn-
trophin PDZ domains. However, nNOS does not appear to
contain any obvious R/K-E-S/T-X-L/M/V-related sequence
within its PDZ domain, or in sequences upstream of the PDZ
domain, which are necessary for strong binding to syntrophin
PDZ domains (38),2 nor does nNOS contain any cysteines in
this region which could potentially form intramolecular disul-
fide bonds. Nevertheless, it should be kept in mind that syn-
trophin PDZ domains may bind to sequences where flanking
amino acids other than cysteines are capable of inducing a
secondary structure conducive to binding.
Collectively, our results suggest that the peptide F sequence
is specific for syntrophin PDZ domains. Rational explanations
for this specificity can be deduced by comparing the solution
structure of the a1-syntrophin PDZ domain complexed with a
C-terminal peptide (G-V-K-E-S-L-V-COOH) (16) to the crystal
structure of the third PDZ domain of PSD-95 complexed with
its peptide ligand (14). Consistent with the idea that syntro-
phin PDZ domains bind C-terminal peptide ligands in a man-
ner similar to PSD-95, amino acids whose side chains are
known to be involved in binding to the general S/T-X-V motif in
PSD-95 are well conserved in syntrophin PDZ domains (14).
Indeed, Schultz et al. (16) have shown that the syntrophin PDZ
domain binding site is structurally conserved. In contrast, res-
idues that are proposed to determine ligand specificity are
strongly conserved in syntrophin PDZ domains, but vary con-
siderably among PDZ domains from different families (16).
These findings account for the identical ligand preferences of
the three syntrophin PDZ domains (21). Moreover, small dif-
ferences in these key residues are likely to explain the unique
ability of syntrophin PDZ domains to bind peptide F.
An unexpected finding of this study was that the SkM2
NaCh C-terminal peptide bound to the PSD-93 and PSD-95
fusion proteins (Fig. 6, SkM2). Since these fusion proteins
contain two and three PDZ domains, respectively, we cannot
conclude at this time which PDZ domain binds the SkM2 pep-
tide. Interestingly though, of the three PDZ domains in PSD-93
and PSD-95, the second PDZ domain in each most closely
resembles syntrophin PDZ domains at the residues described
by Schultz et al. (16). These similarities may explain why
syntrophin PDZ domains bind to some extent to many of the
same C-terminal peptide sequences as the second PDZ domain
of PSD-93 and PSD-95, including NR2B, Kv1.4, and SkM2 (21)2
and to the nNOS PDZ domain (11). This observation raises the
possibility that the PDZ domains of syntrophins, PSD-93, and
PSD-95 compete for similar ligands.
In summary, our results suggest that syntrophin PDZ do-
mains can potentially interact with target proteins via three
different modes of binding. (i) Syntrophins bind skeletal muscle
NaChs and target them to the DAPC through the interaction of
the PDZ domain with C-terminal S/T-X-V-COOH sequences
(21). (ii) Syntrophins also mediate the membrane localization of
nNOS in skeletal muscle by forming presumptive heterodimers
with a N-terminal PDZ domain in nNOS (11). (iii) Syntrophin
PDZ domains may also be capable of interacting with internal,
conformationally constrained, sequences in other proteins.
Such proteins may play a role in modulating the localization or
function of nNOS and NaChs in skeletal muscle or brain.
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